Biosimilars

An Obvious Solution to Lowering U.S. Health Care costs

Biosimilars are lower-cost alternatives to originator biologic medicines and are safe, effective and FDA-approved. So why aren’t biosimilars being used to lower drug costs?

Biologics

Biologics medicines are complex therapies made by living cells and used to treat some of life’s most serious diseases, including cancers, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and Crohn’s Disease. Their capacity to precisely target signaling pathways and cells is revolutionizing the battle against challenging diseases.

Biologics are more difficult to manufacture than traditional medicines, and while they account for less than one percent of prescriptions filled, these products equal close to one-third of all drug spending. Moreover, biologics represent 70 percent of the growth in drug spending from 2010 to 2015.

Increased access to biosimilars could cut U.S. health care spending by as much as $54 billion over the next decade.

RAND Corporation

If Americans had the opportunity to purchase FDA-approved biosimilars, they could have saved more than $4.5 billion in 2017.

U.S. Food and Drug Administration

Biosimilars

Biosimilars are lower-cost alternatives to originator biologic medicines, and have no clinically meaningful differences in the safety profile, potency, and purity as compared to the reference biologics. Key to the biosimilars experience is that they perform the same in clinical practice. The FDA approves biosimilars only after they meet the agency’s rigorous standards for approval.

Because biosimilars create new choices and competition in the biologics marketplace, they lower costs for patients and the health care system, bringing patients more options when battling challenging diseases.

Biosimilars can cost up to 30 percent less than reference biologics, and they have the potential to save the United States billions of dollars.

The promise of biosimilars means expanding treatment options for patients, potentially improving patient outcomes by increasing or providing earlier access to therapies. It’s time policymakers and stakeholders work to increase access to biosimilars to save health care dollars.

Biosimilars

Biosimilars are lower-cost alternatives to originator biologic medicines, and have no clinically meaningful differences in the safety profile, potency, and purity as compared to the reference biologics. Key to the biosimilars experience is that they perform the same in clinical practice. The FDA approves biosimilars only after they meet the agency’s rigorous standards for approval.

Because biosimilars create new choices and competition in the biologics marketplace, they lower costs for patients and the health care system, bringing patients more options when battling challenging diseases.

Biosimilars can cost up to 30 percent less than reference biologics, and they have the potential to save the United States billions of dollars.

The promise of biosimilars means expanding treatment options for patients, potentially improving patient outcomes by increasing or providing earlier access to therapies. It’s time policymakers and stakeholders work to increase access to biosimilars to save health care dollars.

Increased access to biosimilars could cut U.S. health care spending by as much as $54 billion over the next decade.

RAND Corporation

If Americans had the opportunity to purchase FDA-approved biosimilars, they could have saved more than $4.5 billion in 2017.

U.S. Food and Drug Administration

Research

The Biosimilars Forum provides evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars in the United States. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

About The Biosimilars Forum

About The Biosimilars Forum

The Biosimilars Forum provides evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars in the United States. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

Contact Us